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        Immunologists have famously catego-
rized diff  erent subsets of T cells and at-
tributed diff  erent biological functions to 
these cell populations. Nearly 40 years 
ago, T cells were divided into helper, 
cytotoxic, and suppressor (now   “  regu-
latory  ”  ) cell types. 20 years later, the Th 
cells were further divided into Th1 and 
Th2 subsets. Th2 T cells were associated 
with allergy, whereas Th1 cells were as-
sociated with various organ-specifi  c au-
toimmune diseases. More recently, a new 
subset of Th cells was described and 
named Th17 based on production of the 
cytokine interleukin (IL)-17 (  1  –  3  ). 
  Although such tidy categorization 
may be attractive in its simplicity, it has 
become apparent that the original Th1/
Th2 paradigm is much more compli-
cated than originally appreciated. Hu-
man diseases such as multiple sclerosis 
(MS) and rheumatoid arthritis (RA), for 
example, were commonly considered to 
be Th1 mediated, but we now realize 
that such generalizations were inaccurate 
and oversimplifi  ed. For over a decade, 
various anomalies that contradicted the 
Th1/Th2 paradigm went unexplained 
(  1  ). One example was the well-known 
fi  nding that in one version of the   “  Th1-
driven  ”   disease experimental autoim-
mune encephalitis (EAE), a mouse model 
of MS, treating mice with the prototype 
Th1 cytokine interferon (IFN)-      actually 
reversed disease, and blocking IFN-      
worsened disease (  4  –  6  ). These fi  ndings 
seem to contradict the idea that Th1 
responses drive EAE and suggest that 
IFN-      may play diverse roles depending 
on the stage of disease, or that certain 
EAE models may not accurately refl  ect 
the human disease. For years, the impli-
cations of these contradictory data went 
largely unchallenged, as the complexities 
of the Th1/Th2 axis in this model of T 
cell  –  mediated autoimmune disease were 
not fully grasped. 
  The identifi  cation of the Th17 sub-
set has now broadened our understand-
ing of infl  ammatory processes in human 
disease and has helped to explain some 
of the anomalies seen in the Th1/Th2 
axis. However, we may now be facing 
similar pitfalls by invoking Th17 cells to 
explain disease processes  —  in particular, 
immune-mediated tissue damage  —  with-
out considering many as yet unexplained 
inconsistencies in the experimental 
data. Immunologists are repeating many 
of the intellectual mistakes that were 
made for Th1/Th2 a decade earlier, as 
we confront the new concept of Th17. 
Two papers in the   Journal of Experimen-
tal Medicine  , one by Luger et al. in a re-
cent issue (  7  ) and another by Kroenke 
et al. (  8  ) on page   1535   of this issue, as 
well as other recent work (  9  –  12  ), help 
provide a more balanced view of the 
role of Th17 cells in autoimmune disease 
and immune-mediated tissue damage. 
  Using a model of experimental au-
toimmune uveitis (EAU), Luger et al. 
(  7  ) showed that either Th1 or Th17 
cells can drive tissue damage depending 
on the methods used to initiate disease. 
In this issue, Kroenke et al. (  8  ) show 
that adoptive transfer of either Th1 or 
Th17 cells can induce EAE and clinical 
paralysis in mice, but the pathology in-
duced by Th17 cells diff  ers from that 
induced by Th1 cells. Thus Th17 cells 
are unlikely to be the sole players in 
driving tissue damage in these classical 
models of autoimmunity. 
  Non  –  IL-17 culprits in tissue damage 
  In our rush to embrace Th17 cells as the 
purveyors of tissue damage, we should 
not forget that cytokines produced by 
Th1 cells and other cell types are criti-
cal in promoting various forms of in-
fl  ammation. Administration of IFN-     , 
for example, worsened disease in pa-
tients with MS (  13  ). And blocking tu-
mor necrosis factor (TNF), which can 
be produced by various cell types, is a 
gold standard for treatment of diseases 
now thought to be driven largely by 
Th17 cells, including RA, Crohn  ’  s dis-
ease, and various forms of psoriasis (  1  ). 
Furthermore, type I IFNs, which are 
therapeutic in MS (  14, 15  ), are patho-
genic in systemic lupus erythematosus 
(  16  ). It is worth noting that the role of 
IL-17 in these major human diseases is 
much less well understood than TNF, 
IFN-     , or type I IFNs. 
  Ex vivo studies have also suggested 
that cytokines of the Th1/Th2 axis 
are critical determinants in mycobacte-
rial diseases ranging from tuberculoid 
leprosy, which is primarily driven by 
IL-12 and Th1 cells, to lepromatous 
leprosy, which is mediated by Th2 cells 
(  17  ). And Th2 responses drive many 
aspects of allergic responses (  3  ). Al-
though Th17 is a welcome addition to 
our understanding of immune-medi-
ated tissue damage, we still need the 
Th1/Th2 axis and other infl  ammatory 
mediators to explain many aspects of 
human autoimmune, allergic, and in-
fectious diseases. 
Some immunologists have characterized T helper (Th)17 T cells as the master 
mediators of tissue damage in a variety of pathological conditions. New data 
now demonstrate that Th1 and Th17 T cells are independently capable of 
inducing disease in two established models of autoimmunity. Thus, the role of 
Th17 cytokines as the central mediators of pathological tissue damage seems 
to require clarifi  cation.
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Th17-polarized myelin-reactive T cells 
induces EAE (  8  ). Ascending paralysis 
ensued in both models, but the cellular 
infi  ltrate induced by Th17 cells was rich 
in neutrophils, whereas macrophages 
predominated the Th1-induced infi  l-
trate  —  a pathological picture similar to 
MS, in which neutrophilic infi  ltration is 
rare. The pathology seen with IL-17  –  in-
duced EAE was reminiscent of that seen 
in acute disseminated encephalomyelitis, 
and other rare demyelinating conditions 
such as Marburg  ’  s disease, and also re-
sembles certain aspects of neuromyelitis 
optica  —  all conditions in which neutro-
phils are common. Neuromyelitis optica 
is also similar to Th17  –  induced EAE in 
that the pathology is most intense in the 
spinal cord and optic nerves. Consis-
tent with this, Stromnes et al. ( 9  ) showed 
that EAE is most intense in the brain 
when Th17/Th1 ratios are high, whereas 
infl  ammation is focused on the spinal 
cord when Th17/Th1 ratios are more 
widely varied. 
  The overall picture that emerges 
suggests that EAE has a variety of his-
tological and anatomical manifestations 
depending on the cytokines produced 
by the disease-inducing T cells (  8, 9  ). 
Thus, one cannot conclude at all that 
EAE is driven by Th17 cells. The data 
from Kroenke et al. ( 8  ) confi  rm that EAE 
can be induced by either Th1 or Th17 
T cells. Finally, earlier work from Lafaille 
et al. (  21  ) indicated that even Th2 cells 
can induce EAE in RAG-defi  cient mice. 
In that study, the cellular infi  ltrate was 
rich in eosinophils. Such pathology re-
plete with eosinophils, typical of allergic 
disorders, would be worthy of the origi-
nal term for EAE,   “  experimental allergic 
encephalomyelitis.  ”   
  Other cytokines like osteopontin 
drive the production of IFN-      (  22, 23  ), 
and osteopontin has also recently been 
shown to drive the production of IL-17 
(  24  ). Osteopontin is critical in trigger-
ing relapses of EAE and is elevated in 
the plasma of patients suff  ering MS re-
lapses (  25  ). Is it thus possible that osteo-
pontin is the main driver of tissue damage 
and MS relapses, and not IFN-      or IL-17? 
It can hardly be concluded at this point 
that Th17 is the sole driver of tissue dam-
age in MS or EAE. 
comparable in wild-type and IL-17  –  de-
fi  cient mice (  7  ). It should be noted that 
many investigators equate the loss of 
IL-17A in the IL-17 
     /       mice (  7  ) with a 
complete loss of Th17 cells, but these 
cells also produce other cytokines, in-
cluding IL-17F, IL-21, and IL-22. Al-
though Luger et al. conclude that the 
development of EAU in IL-17 
     /       mice 
required an IFN-       –  producing eff  ector 
T cell, they did not formally rule out a 
role for other Th17 cytokines (  7  ). 
  These results are diffi   cult to interpret 
given other studies showing a protective 
role for IFN-      in EAU. Neutralization 
of IFN-      has been shown to exacerbate 
EAU, just as it does EAE (  4  –  6  ). Further-
more, EAU develops effi   ciently in mice 
depleted of IFN-     , and, perplexingly, 
recombinant IFN-      has been shown to 
protect against disease (  19, 20  ). How, 
then, could an IFN-       –  producing eff  ec-
tor cell be important for the pathogenesis 
of EAU, if recombinant IFN-      is itself 
protective? These results must be con-
sidered paradoxical and problematic at 
the least. Akin to the anomalies and par-
adoxes seen with Th1 cells in EAE, these 
results are probably telling us something 
highly important, although we do not 
yet have enough knowledge to explain 
it. But the data certainly confl  ict with 
the notion of IL-17 as a master mediator 
of tissue damage, at least in EAU. 
  Luger et al. went on to induce EAU 
by immunizing mice with IRBP-pulsed 
dendritic cells, a model that is indepen-
dent of CFA (  Fig. 1 C  ). In this model, 
the disease was characterized by an infl  ux 
of T cells that produce large amounts 
of IFN-      but little IL-17. And IFN-       –
  defi  cient mice immunized with IRBP-
pulsed dendritic cells were protected 
against disease despite the robust pro-
duction of IL-17 (  7  ). It is possible that 
the use of adjuvants in certain animal 
models of autoimmune disease, such as 
EAE, EAU, and collagen-induced ar-
thritis, might skew the importance of 
IL-17. Indeed, the presence of adjuvants 
that, like CFA, contain killed myco-
bacteria might provide a critical clue to 
explain the discrepancies between dif-
ferent models. 
  In this issue, Kroenke et al. show 
that adoptive transfer of either Th1- or 
  Th17 cells as disease inducers 
  In a recent issue of the   JEM  , Luger et al. 
(  7  ) demonstrated that IL-17 and IL-23, 
a cytokine that drives expansion of Th17 
cells, are important in the pathogenesis 
of EAU, a model that refl  ects many as-
pects of both infectious and autoimmune 
uveitis in man. In that study, adminis-
tration of antibodies against IL-17 in-
hibited the development of EAU after 
immunization with the retinal antigen 
intra-retinal binding protein (IRBP) in 
complete Freund  ’  s adjuvant (CFA), and 
also reversed established disease (  7  ). Anti-
bodies against IL-23 also aborted the 
development of EAU in this model, but 
only when given early in the disease 
(  Fig. 1 A  ).   Blocking IL-23 was no lon-
ger eff  ective by day 7, a time when T 
cells capable of inducing uveitis were 
  already present. The authors thus con-
cluded that IL-23 is important for the 
priming of uveitis-inducing T cells, but 
not for their eff  ector function. Support-
ing a role for IL-23 in EAU induction, 
mice lacking the IL-23 subunit p19 or 
p40, which is also shared by IL-12, were 
protected against disease. Mice lacking 
the IL-12  –  only subunit p35, by contrast, 
were more susceptible to EAU than were 
wild-type mice (  Fig. 1 A  ). Finally, trans-
fer of in vitro  –  polarized, IRBP-specifi  c 
Th17 cells into recipient mice triggered 
EAU, even in the complete absence of 
IFN-      (  Fig. 1 B  ). 
  These fi  ndings in EAU are similar to 
studies in EAE, in which chronic dis-
ease is reduced in IL-17 
     /       mice, although 
these mice still develop acute paralysis 
of their hind limbs (  18  ). Adoptive trans-
fer of myelin-reactive T cells from IL-
17 
     /       mice into wild-type mice also leads 
to much milder EAE, as measured by 
incidence and severity of paralysis, com-
pared with transfer of myelin-reactive T 
cells from wild-type mice (  18  ). 
  Th17 cells as innocent bystanders 
  Other data from Luger et al., however, 
suggested that EAU can also develop in 
the absence of Th17 cells. Transfer of a 
Th1 clone specifi  c for IRBP, for exam-
ple, caused severe disease in the absence 
of IL-17 production (  Fig. 1 B  ). More-
over, disease severity in response to im-
munization with IRBP plus CFA was JEM VOL. 205, July 7, 2008  1519
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    Figure 1.         Th17 or Th1 cells can induce EAU depending on the method of disease induction  . (A) Direct vaccination model. Disease was induced 
by immunizing mice with IRBP plus CFA. There was a signifi  cant reduction of EAU in p19 and p40 knockout mice, with a signifi  cant increase in EAU in p35 
knockout mice compared with wild type. Antibody blockade of IL-17 reduced disease when given either during disease induction or after disease onset, 
whereas antibody blockade of IL-23 reduced disease only when administered during disease induction. (B) T cell transfer model. Transfer of Th1-polarized, 
IRBP-specifi  c CD4 
+   T cells induced EAU (top). In this model, blocking IL-17 had no effect on disease and blocking IFN-      ameliorated disease. Transfer of 
Th17-polarized, IRBP-specifi  c CD4 
+   T cells induces EAU (bottom), and, in this model, disease was equivalent when cells were transferred into IFN-     – defi  -
cient mice. (C) Dendritic cell immunization protocol. IRBP-pulsed mature dendritic cells were injected into mice, followed by pertussis toxin at day 2. In 
this model, disease was decreased in IFN-     – defi  cient mice, despite an increased production of IL-17 in the central nervous system as compared with 
wild-type  mice.   1520 CAVEATS FOR TH17 | Steinman
that its signature function as the mediator 
of organ-specifi  c tissue damage in auto-
immunity and other forms of pathology 
should be refi  ned. Exceptions always 
teach us something important, as we have 
learned from our evolving understand-
ing of the Th1/Th2 paradigm (  1  ). The 
Th17 pathway has many divergent roles 
in models of autoimmune, infectious, 
and allergic disease. 
  Indeed, IL-17 is not even a purely 
Th17 cytokine because it is also made by 
macrophages (  40  ), astrocytes (  41  ), oligo-
dendroglia (  41  ), uterine fi  broids  (  42  ), 
and corneal epithelial cells on the surface 
of the eye (  43  ). In fact, IL-17 was fi  rst 
cloned from mouse NKT cells (  44  ). Fi-
nally, what drives Th17 is not altogether 
certain. Emerging data indicate that mol-
ecules such as osteopontin drive both 
Th1- and Th17-mediated tissue damage 
(  22  –  25  ). We might thus be heading to-
ward the conclusion that no single mol-
ecule or Th pathway dominates and that 
there is no hierarchical scheme at all. 
  It is diffi   cult to understand how so 
many immunologists developed such 
exuberant enthusiasm for Th17 in the 
fi  rst place, placing it in a starring and 
paramount role for all immune-medi-
ated tissue damage. One of the groups 
who was instrumental in the discovery 
and elucidation of this pathway recently 
reviewed the subject with a balanced 
perspective (  2  ). They enumerated the 
multiplicity of   “  inconvenient truths  ”   
that befuddled this role for Th17 when 
they asked,   “  But are Th17 cells the only 
eff  ector cells capable of inducing organ-
specifi  c autoimmunity? Mice defi  cient 
in T-bet and STAT-4, and thus lacking 
Th1 cells (  45, 46  ), have overwhelm-
ingly large numbers of Th17 cells (  47, 
48  ) and yet are resistant to EAE (  47  –
  49  ). Do those data suggest that Th1 
cells are pathogenic and Th17 cells are 
not? The truth is probably somewhere 
in the middle. For many reasons, we 
support the idea that both Th1 and 
Th17 cells are capable of inducing au-
toimmunity  ”   (  2  ). 
  An emerging conclusion is that tis-
sue damage and protection are nuanced 
and are governed by multiple/redun-
dant molecular interactions that involve 
many cytokines, including the type I 
TGF-     , were critical for the priming of 
Th17 responses (  29, 30  ). In one of those 
studies, TGF-      suppressed IL-17 pro-
duction (  29  ). More recent data, however, 
revealed that TGF-     , IL-1      and IL-6, 
IL-21, or IL-23 (in serum-free condi-
tions) could induce IL-17 production 
from naive human CD4 T cells from 
umbilical cord blood (  31  ). TGF-      sup-
pressed ROR-     t  –  induced IL-17 ex-
pression, but this suppression was relieved 
in the presence of infl  ammatory cyto-
kines. Another study showed that TGF-      
was essential, along with IL-23, IL-1     , 
and IL-6 for Th17 diff  erentiation (  32  ). 
Yet another showed that TGF-      en-
hanced IL-17 in peripheral T cells (  33  ). 
At this point it appears that IL-1      and 
IL-6 drive IL-17A production from 
central memory CD4 
+   T cells, whereas 
TGF-      and a constellation of other in-
fl  ammatory cytokines promote the dif-
ferentiation of naive CD4 
+   T cells into 
Th17 cells (  34  ). 
  The role of TGF-      is highly pleio-
tropic (  35, 36  ). Local induction of TGF-
      in mouse brain, for example, leads to 
induction of EAE (  36  ), and its pharma-
cologic suppression reverses paralytic 
disease (  37  ). TGF-      signaling in the 
brain leads to increased production of 
IL-6, which then enhances infl  amma-
tion (  37  ). TGF-      is elevated in chronic 
MS lesions, in which there is also intense 
production of IL-17 from astrocytes and 
oligodendroglia (  38  ). Thus, TGF-      
might promote IL-17 production during 
the chronic active phase of MS (  9, 38  ). 
  Studies in humans have also revealed 
the existence of T cell clones in the in-
testines of patients with infl  ammatory 
bowel disease that produce both IL-17 
and IFN-     , and are thus designated Th1/
Th17 cells. These dual producers can 
also be found in EAE lesions in mice 
(  39  ) and express both the Th17-inducing 
transcription factor ROR-     t and the 
Th1-inducing transcription factor T-bet. 
The biological importance of these hy-
brid Th1/Th17 clones is as yet unclear. 
  Concluding remarks 
  Immunologists ought to be restrained in 
attributing too much to the Th17 path-
way at this stage. The plentiful excep-
tions outlined in this commentary suggest 
  Th17 cells as protectors 
  Another issue that must be considered is 
that IL-17 would not have evolved if it 
only did harm. The protective side of 
IL-17 was demonstrated in a recent study 
of mycobacteria tuberculosis infection, 
in which IL-17 was required to recruit 
protective IFN-       –  producing CD4 
+   T 
cells into the lung (  26  ). In an asthma 
model, neutralization of IL-17 increased 
eosinophilic infi  ltration during the eff  ec-
tor phase of disease, and administration 
of recombinant IL-17 diminished airway 
hyperreactivity and reduced the num-
bers of eosinophils and lymphocytes in 
bronchial lavage (  27  ). In this model of 
asthma, IL-17 thus appears to be a nega-
tive regulator of established disease (  27  ). 
How can we continue to call the Th17 
pathway the critical mediator of immune-
mediated tissue damage with such counter 
examples from autoimmunity, infectious 
disease, and allergic disease? 
  Th17 in mouse and in man 
  The ultimate signifi  cance of the Th17 
pathway in human disease remains un-
clear, and we are only now clarifying the 
details of the Th17 pathway in humans. 
The fi  rst analyses of the Th17 pathway 
came from studies of experimental dis-
eases in mice, and the fi  rst studies on the 
Th17 in man revealed signifi  cant diff  er-
ences. As Natalie Angier wrote in her 
elegant book   The Canon  ,   “  Whether siz-
ing up new acquaintances or seizing on 
novel ideas, we remain forever at the 
mercy of our fi  rst impressions  ”   (  28  ). In 
immunology (at least these days), our 
fi  rst impressions often come from mice. 
Again to quote Angier, we should ana-
lyze the source of our misconceptions, 
and then we   “  have a chance of amend-
ing, remodeling, or blowtorching them 
as needed, and replacing them with a 
closer approximation of science  ’  s approxi-
mate truths  ”   (  28  ). 
  The parallels between mouse and 
man fi  rst diverged in defi  ning a role for 
transforming growth factor (TGF)-      in 
the diff  erentiation of Th17 cells. In mice, 
IL-6 and TGF-      are required for the 
production of IL-17 (  2  ). Two initial hu-
man studies, however, showed that IL-6 
and IL-1      (produced by monocytes 
or conventional dendritic cells), but not JEM VOL. 205, July 7, 2008  1521
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